Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Sacubitril valsartan (ARNI) is an export arteriolar dilator as well as an import arteriolar dilator and has been established as a key drug for HFrEF, but its use in CKD has not been established.
SGLT2 inhibitors are essential in the treatment of CKD because of their renoprotective effect by correcting intraglomerular pressure through tubuloglomerular feedback. Controlling the initial dip may lead to continuation of the medication and renoprotective effect. In this study, we investigated the possibility of controlling the initial dip by the imported arteriolar dilating effect of ARNI.
148 patients (group 1) were prescribed SGLT2 inhibitors (dapagliflozin and empagliflozin) in 2022-2024. eGFR decline of ≥5% at visit within 3 months after SGLT2 inhibitor prescription was defined as initial dip and its occurrence was defined as outcome. The relationship between ARNI at the time of SGLT2 prescription and the presence of initial dip was examined by logistic regression analysis using age, male, BMI, systolic blood pressure, DM, hemoglobin, BUN, eGFR baseline, and urinary protein as adjustment factors. In addition, we also analyzed eGFR decline 1 year after initiation of SGLT2 inhibitors using a mixed regression model (group2, n=134).
Taking ARNI was associated with the occurrence of initial dip [OR=0.24 (95%CI, 0.06-0.95, p=0.04)]. The analysis of eGFR decline at 1 year after initiation of SGLT2 inhibitors showed that the presence or absence of ARNI was not associated with eGFR decline.
In group2, eGFR decline at 1 year was analyzed using a mixed model, and no association was found between ARNI use and eGFR decline (p=0.82).
Taking oral ARNI may suppress the initial dip caused by SGLT2 inhibitors. No effect of oral ARNI on eGFR decline was suggested, but long-term follow-up is needed to confirm this.
